Bill Ackman’s Pershing Square Capital Management is having a tough time this year and he can partly thank Wall Street’s sell-side analysts for his woes.
In the past few days, he has found himself on the opposite side of research recommendations on his two most controversial holdings—Herbalife and JC Penney.
